TeraPore Technologies

Executive Summary

TeraPore Technologies is a private company based in San Francisco, founded in 2015, that has developed a tunable self-assembled block copolymer technology for advanced nanofiltration. This platform addresses critical separation challenges in biopharmaceutical production, particularly virus filtration for novel biologics, as well as in semiconductor manufacturing. By enabling precise pore size control, TeraPore's products aim to improve yield, purity, and efficiency compared to conventional filtration methods. The company targets the rapidly growing biologics market, where demand for high-performance virus removal filters is rising due to stricter regulatory requirements and the shift toward complex modalities like gene therapies and monoclonal antibodies. TeraPore has not disclosed its total funding or valuation, but its technology has garnered interest from industry players. The company's stage is early commercial or pre-revenue, with potential to disrupt the filtration market. Its success hinges on scaling manufacturing, securing regulatory approvals, and forming partnerships with major biopharma and semiconductor firms. TeraPore's innovative approach positions it well for growth, though it faces competition from established players like Pall and Sartorius. Given the strategic importance of filtration in drug safety and semiconductor fabrication, TeraPore represents a compelling investment opportunity in the advanced materials space.

Upcoming Catalysts (preview)

• Q3 2026Series B Funding Close70% success
• Q4 2026Strategic Partnership with a Top Biopharma Company50% success
• Q1 2027Commercial Launch of Virus Filtration Product40% success